公开(公告)号：US08802240B2

公开(公告)日：2014-08-12

申请号：US13345194

申请日：2012-01-06

Applicant: Paul J. Davis ,  Shaker A. Mousa

Inventor： Paul J. Davis ,  Shaker A. Mousa

IPC: A61K31/198 ,  A61K31/192 ,  A61K31/704 ,  A61P29/00

CPC classification number: C07K16/2848 ,  A61K31/192 ,  A61K31/198 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K39/39533 ,  A61K45/06 ,  A61K2039/505 ,  B82Y5/00 ,  Y10T428/12729 ,  Y10T428/31815 ,  A61K2300/00

Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.

Abstract translation: 公开了使用甲状腺激素类似物和/或其纳米颗粒或聚合物形式增加正常和/或化学抗性肿瘤或癌细胞的化学敏感性的方法。 还公开了使用甲状腺激素类似物和/或其纳米颗粒或聚合形式增加正常和/或放射抗性肿瘤或癌细胞的放射敏感性的方法。

公开(公告)号：US20110104283A1

公开(公告)日：2011-05-05

申请号：US12912826

申请日：2010-10-27

Applicant: Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

Inventor： Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

IPC: A61K38/46 ,  A61P19/00 ,  A61K9/14 ,  A61K33/32 ,  A61K33/06 ,  A61P19/10

CPC classification number: A61K36/31 ,  A61K9/5146 ,  A61K9/5161 ,  A61K31/593 ,  A61K33/06 ,  A61K33/32 ,  A61K38/4873 ,  A61K45/06 ,  C12Y304/22033 ,  A61K2300/00

Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.

Abstract translation: 用于治疗动物骨骼状况的组合物和方法。 组合物包括活性成分的纳米制剂。 活性成分包括莴苣（Lepidium Sativum）或其他百日咳提取物，钙，维生素D和抗氧化剂。 用于治疗骨骼状况的方法包括将组合物引入动物体内。

公开(公告)号：US20110052715A1

公开(公告)日：2011-03-03

申请号：US12816287

申请日：2010-06-15

Applicant: Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinsky ,  Aleck Hercbergs

Inventor： Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinsky ,  Aleck Hercbergs

IPC: A61K9/14 ,  B32B5/00 ,  C07K14/575 ,  A61K31/74 ,  A61K38/22 ,  A61K38/18 ,  A61P5/14 ,  B82Y5/00

CPC classification number: A61K9/5031 ,  A61K31/192 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K47/643 ,  A61K47/645 ,  A61K47/6455 ,  A61K47/6937 ,  B82Y5/00 ,  Y10T428/2982

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素激动剂，部分激动剂或其拮抗剂的聚合物纳米颗粒形式，以促进或抑制受试者的血管发生。 还公开了甲状腺激素或甲状腺激素类似物的纳米颗粒形式及其用途。

公开(公告)号：US20230414556A1

公开(公告)日：2023-12-28

申请号：US18212228

申请日：2023-06-21

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/352 ,  A61K9/51 ,  A61K31/05 ,  A61K31/12 ,  A61K31/375 ,  A61P3/06

CPC classification number: A61K31/352 ,  A61K9/5161 ,  A61K9/5123 ,  A61K31/05 ,  A61K31/12 ,  A61K31/375 ,  A61P3/06

Abstract: A nanoparticle structure and a method for lowering lipids in a mammal by administering the nanoparticle structure to the mammal. The nanoparticle structure includes a hepatic targeted nanoparticle and one or more substances encapsulated within the hepatic targeted nanoparticle. The nanoparticle includes chitosan and glycyrrhetinic acid (GA) covalently linked by an amide bond which occurs between an amino group of chitosan and a carboxylic acid group of GA. The one or more substances comprise (−)-Epigallocatechin-3-gallate (EGCG).

公开(公告)号：US09956181B2

公开(公告)日：2018-05-01

申请号：US15260967

申请日：2016-09-09

Applicant: Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed-Salleh M. Ardawi

Inventor： Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed-Salleh M. Ardawi

IPC: A61K9/50 ,  A61K31/01 ,  A61K9/19 ,  A61K9/51 ,  A61K9/16 ,  A61K31/353 ,  A61K47/59 ,  A61K47/69

CPC classification number: A61K31/01 ,  A61K9/1652 ,  A61K9/19 ,  A61K9/5031 ,  A61K9/5036 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K9/5161 ,  A61K31/353 ,  A61K47/59 ,  A61K47/6925

Abstract: A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized (−)-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.

公开(公告)号：US09770419B2

公开(公告)日：2017-09-26

申请号：US13953888

申请日：2013-07-30

Applicant: Shaker A. Mousa ,  Abdulqader Al Haider ,  Abdelgalil Abdelgader ,  Abdullah M. Aldahmash ,  Abdulkareem Almomen

Inventor： Shaker A. Mousa ,  Abdulqader Al Haider ,  Abdelgalil Abdelgader ,  Abdullah M. Aldahmash ,  Abdulkareem Almomen

IPC: A61K47/42 ,  A61K31/726 ,  A61K31/728 ,  A61K31/738 ,  A23C9/152 ,  A23P10/30 ,  A23L33/19 ,  A61K9/48 ,  A61K31/337 ,  A61K31/704 ,  A61K31/12 ,  A61K31/727 ,  A61K47/48 ,  A61K9/51 ,  A23G9/00 ,  A61K8/63 ,  A61K8/64 ,  A61Q11/00 ,  A61K8/73 ,  A61K8/02 ,  A61K38/00

CPC classification number: A61K9/4866 ,  A23C9/152 ,  A23C2260/152 ,  A23G9/00 ,  A23L33/19 ,  A23P10/30 ,  A23V2002/00 ,  A61K8/0283 ,  A61K8/63 ,  A61K8/64 ,  A61K8/73 ,  A61K8/736 ,  A61K9/5153 ,  A61K9/5169 ,  A61K31/12 ,  A61K31/337 ,  A61K31/704 ,  A61K31/726 ,  A61K31/727 ,  A61K31/728 ,  A61K31/738 ,  A61K38/00 ,  A61K47/42 ,  A61K47/644 ,  A61K47/68 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2800/413 ,  A61Q11/00 ,  A23V2200/25 ,  A23V2250/54246 ,  A23V2250/54248

Abstract: The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (GAG)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof. The nanoparticles are lactoferrin nanoparticles including camel derived lactoferrin, casein nanoparticles including camel derived casein, or combinations thereof. The dairy product includes ice cream or frozen yogurt, wherein the ice cream or frozen yogurt includes the composition and is derived from camel milk or other species of milk. The method for treating a disorder in a subject includes administering a therapeutic dose of the composition to the subject.

公开(公告)号：US09220788B2

公开(公告)日：2015-12-29

申请号：US12816287

申请日：2010-06-15

Applicant: Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinksy ,  Aleck Hercbergs

Inventor： Paul J. Davis ,  Faith B. Davis ,  Shaker A. Mousa ,  Gennadi V. Glinksy ,  Aleck Hercbergs

IPC: A61K9/50 ,  A61K47/48 ,  A61K41/00 ,  B82Y5/00

CPC classification number: A61K9/5031 ,  A61K31/192 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K47/643 ,  A61K47/645 ,  A61K47/6455 ,  A61K47/6937 ,  B82Y5/00 ,  Y10T428/2982

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素激动剂，部分激动剂或其拮抗剂的聚合物纳米颗粒形式，以促进或抑制受试者的血管发生。 还公开了甲状腺激素或甲状腺激素类似物的纳米颗粒形式及其用途。

公开(公告)号：US09198887B2

公开(公告)日：2015-12-01

申请号：US14078713

申请日：2013-11-13

Applicant: Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

Inventor： Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

IPC: A61K31/192 ,  A61K45/06 ,  A61K31/7068 ,  A61K31/225 ,  A61K31/337 ,  A61K31/704

CPC classification number: A61K31/192 ,  A61K31/225 ,  A61K31/337 ,  A61K31/704 ,  A61K31/7068 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素或其拮抗剂的聚合形式，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US20150223451A1

公开(公告)日：2015-08-13

申请号：US14614849

申请日：2015-02-05

Applicant: Shaker A. Mousa ,  Amna Saddiq

Inventor： Shaker A. Mousa ,  Amna Saddiq

IPC: A01N25/10

CPC classification number: A01N25/28 ,  A01N35/04 ,  A01N63/02

Abstract: The composition of the Nano carrier or Nano polymers composed of Hyaluronic Acid (15-25%) and fatty acids (50-70%) cross linked with ultra-Low molecular weight chitosan (15-25%) encapsulating isolated compounds from musk and their combinations for cosmetic use as anti-aging, anti-microbial, and fragrance. Additionally, these nano-encapsulated Musk bioactive compounds (MBC) at 0.1-10% (w/w MBC/Nano polymers) could be used in textile manufacturing (carpet/rugs and clothes) to provide anti-microbial and fragrance properties. Furthermore, Musk derived products are chemically conjugated to HA polymer, FA polymer, CH polymer, HA-CH co-polymer, FA-CH co-polymer or HA-CH-FA co-polymer to be incorporated into the fabric of the textile products (carpet/rugs or clothes).

Abstract translation: 由透明质酸（15-25％）和脂肪酸（50-70％）组成的纳米载体或纳米聚合物的组合物与超低分子量壳聚糖（15-25％）交联，从麝香和其他物质中包裹分离的化合物 化妆品用作抗老化，抗微生物和香料的组合。 另外，0.1-10％（w / w MBC /纳米聚合物）的这些纳米包裹的麝香生物活性化合物（MBC）可用于纺织品制造（地毯/地毯和衣服），以提供抗微生物和香料特性。 此外，麝香衍生物与HA聚合物，FA聚合物，CH聚合物，HA-CH共聚物，FA-CH共聚物或HA-CH-FA共聚物化学键合，以结合到纺织品的织物中 （地毯/地毯或衣服）。

公开(公告)号：US20150150818A1

公开(公告)日：2015-06-04

申请号：US14526950

申请日：2014-10-29

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K9/48 ,  A61K47/42 ,  A61K47/36 ,  A61K31/737

CPC classification number: A61K31/737 ,  A61K9/5169 ,  A61K47/6939

Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.

Abstract translation: 包含纳米颗粒的组合物。 纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳。 壳包括聚L-精氨酸。 SNACH离子或共价键合到聚L-精氨酸。 用于治疗受试者疾病的方法包括：向受试者施用治疗有效量的用于治疗病症的组合物。 该疾病是血管疾病，血管疾病的并发症或其组合。